Clinical Trial Update: Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH) [NA]

View source ↗

Summary

Xeltis is conducting a first-in-human trial of the XABG coronary bypass graft for multi-vessel coronary artery disease, with enrollment by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease

Drugs mentioned

• XABG (Xeltis Coronary Artery Bypass Graft)

Snippet

Sponsor: Xeltis | Conditions: Multi Vessel Coronary Artery Disease | NA | Status: ENROLLING_BY_INVITATION